ERBB3 and melanoma: Interestingly, inhibitors of other classes of kinases relevant to melanoma such as vemurafenib, which target mutated BRAF, did not synergize with fucoidan (Supplementary Figure 4), suggesting this natural compound amplifies the effects of inhibitors that target ERBB3 signaling.